Clinical Trials Logo

CLL Progression clinical trials

View clinical trials related to CLL Progression.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04149821 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Start date: February 10, 2021
Phase: Phase 2
Study type: Interventional

This study evaluates the efficacy and safety of umbralisib and ublituximab (U2) as salvage therapy in patients with chronic lymphocytic leukemia (CLL) who have progressed either on a BTK inhibitor (BTKi) or BCL-2 inhibitor. The study will evaluate this combination in two parallel cohorts and subjects will be assigned based on which class of novel agent-containing regimen was used prior. Cohort A will consist of patients who progress after BTKi containing regimens and Cohort B will consist of patients who progress after a BCL-2 containing regimen. Subjects who progress on a regimen containing both a BTKi and a BCL-2 inhibitor, will be enrolled in cohort B. Each cohort will be evaluated independently of each other.